RT Journal Article
SR Electronic
T1 Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21263288
DO 10.1101/2021.09.08.21263288
A1 Benade, M
A1 Rosen, S
A1 Antoniak, S
A1 Chasela, C
A1 Stopolianska, Y
A1 Barnard, T
A1 Gandhi, MM
A1 Ivanchuk, I
A1 Tretiakov, V
A1 Dible, J
A1 Minior, T
A1 Chew, KW
A1 van der Horst, C
A1 Tsenilova, Z
A1 Sanne, I
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263288.abstract
AB Background Direct-acting antivirals (DAAs) are highly effective in achieving sustained virologic response among those with chronic hepatitis C virus (HCV) infection. Quality of life (QOL) benefits for an HCV-infected population with high numbers of people who inject drugs and people living with HIV (PLHIV) in Eastern Europe have not been explored. We estimated such benefits for Ukraine.Methods Using data from a demonstration study of 12-week DAA conducted in Kyiv, we compared self-reported QOL as captured with the MOS-SF20 at study entry and 12 weeks after treatment completion (week 24). We calculated domain scores for health perception, physical, role and social functioning, mental health and pain to at entry and week 24, stratified by HIV status.Results Among the 857 patients included for the final analysis, health perception was the domain that showed the largest change, with an improvement of 85.7% between entry and week 24. The improvement was larger among those who were HIV negative (104.4%) compared to those living with HIV (69.9%). Other domains that showed significant and meaningful improvements were physical functioning, which improved from 80.5 (95% CI: 78.9-82.1) at study entry to 89.4 (88.1-90.7) at 24 weeks, role functioning (64.5 [62.3-66.8] to 86.5 [84.9-88.2], social functioning (74.2 [72.1-76.2] to 84.8 [83.2-86.5] and bodily pain (70.1 [68.2-72.0] to 89.8 [88.5-91.1]). Across all domains, QOL improvements among PLHIV were more modest than among HIV-negative participants.Conclusion QOL improved substantially across all domains between study entry and week 24. Changes over the study period were smaller among PLHIV.Competing Interest StatementDr Kara W. Chew has received a research grant to the institution from Merck Sharpe & Dohme. The remaining authors declare that they have no competing interests.Clinical TrialNCT04038320Funding StatementThis work was supported by USAID EQUIP Grant No. AID-OAA-A-1500070 to Right to Care and Luxemburg Business Partnership Facility 2017, Grant No. MAE/014 - 17 1620.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by the Ukranian Institute on Public Health Policy IRB #1, Institutional Review Board (00007612) and the University of Witwatersrand Human Research Ethics Committee (M17078). The Boston University Institutional Review Board approved analysis of a de-identified analytic dataset (H-37820). All participants provided written informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request